AU · rank #16 · 2026-07-21
BN
PARIS · EUR · $53.59B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.330 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.03 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 6 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $80.50 | +10.1% |
| Momentum acceleration 3-month minus 12-month momentum. | +8.08% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 3.86 |
| Gross margin TTM | +50.6% |
| 52w high | $77.37 |
| Market cap (USD) | $53.59B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Danone is a €53.6bn global packaged food company with diversified revenue across dairy/plant-based, waters, and specialized nutrition, reporting €27.3bn in FY25 sales with a 13.4% recurring operating margin.
Rationale
With 75% analyst revision agreement, 6 net upward EPS revisions over 30 days, a 10.1% consensus price target upside, and Q1 2026 results slightly beating consensus despite the infant formula recall headwind, the analyst upgrade cycle appears early-stage and grounded in recovering fundamentals rather than pure sentiment.
Material risks
- 1The ongoing infant formula recall in Europe could escalate into a sustained brand-trust and volume impairment in Specialized Nutrition — Danone's highest-margin segment — directly undermining the earnings revision trajectory that drives this signal.
- 2Euro strength and persistent FX translation headwinds are already converting +2.7% like-for-like Q1 growth into a reported -2% decline, which risks stalling reported EPS upgrades and capping the analyst target upside even if underlying execution improves.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.